Company
Sydney, NSW
Every investor coverage indicates participated in a round sunshineHeart raised.
Investors whose own portfolio pages list sunshineHeart, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Talu Ventures | its portfolio page ↗ |
Companies sunshineHeart acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming sunshineHeart. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures' news page points to an attached document announcing Sunshine Heart's appointment of Warren Watson to its board; the page itself carries only the headline and date.
GBS Ventures reposts a 2013 notice that Sunshine Heart signed a $25 million financing agreement with Aspire Capital Fund, with details only in an attached download.
Brief November 2012 notice reporting that Sunshine Heart won unconditional American regulator clearance to run a pivotal United States trial of its C-Pulse heart device, with detail left to an attached document.
A bare stub on GBS Ventures' site dated December 2011, pointing readers to a downloadable ASX announcement about Sunshine Hearts; the page itself gives no details of the announcement's contents.
A stub news post on GBS Ventures' site flagging that Sunshine Heart's feasibility trial findings were due for presentation at a cardiology conference, with an attached document available for download.
A brief 2011 post from GBS Ventures linking to an attached ASX announcement about early results from Sunshine Heart's C-Pulse feasibility trial, released by Ohio State.
A brief 2011 notice recording that Sunshine Heart brought in A$7.4 million through a two-part private placement, with the ASX filing attached for download.
Profile of Sunshine Heart's C-Pulse heart pump, its US trials and trial funding plans, recalling the failure of fellow Australian device maker Ventracor during the global financial crisis.
A short GBS Ventures news post from May 2011 pointing readers to an attached CEO update document about Sunshine Heart; the page itself gives no details.
A brief GBS Ventures notice pointing readers to an attached document about the stock exchange's query to Sunshine Heart over a recent movement in its share price.
Sunshine Heart's chief executive reports to shareholders on the C-Pulse trial: halfway through its US feasibility study, first two minimally invasive implants completed and new hospitals in Australia, Canada and the US joining.
A reposted ASX announcement from Sunshine Heart reports the first minimally invasive implant of its C-Pulse heart assist system, carried out in early June by a Louisville surgeon under a US FDA feasibility trial.
A 2009 GBS Ventures news stub whose only content is a download link to a document about Sunshine Heart's first implants of its Pulse device; the page itself states no deal, amount or people.
Heart device company Sunshine Heart added cardiologists Marc Silver and David Kaye to its medical advisory board in mid-2006, expanding a panel that guides work on its C-Pulse heart failure treatment.